Proteome analysis has been applied in multiple studies in the context of chronic kidney disease, aiming to improving our knowledge on the molecular pathophysiology of the disease. The approach is generally based on the hypothesis that proteins are key in maintaining kidney function, and disease is a clinical consequence of a significant change of the protein level. Knowledge on critical proteins and their alteration in disease should in turn enable identification of ideal biomarkers that could guide patient management. In addition, all drugs currently employed target proteins. Hence, proteome analysis also promises to enable identifying the best suited therapeutic target, and, in combination with biomarkers, could be used as the rationale basis for personalized intervention.
Chronic kidney disease (CKD) is one of the most concerning diseases of our society both at the European scale and worldwide. CKD affects 10% of the adult population. 70 million Europeans have been diagnosed with some loss of their kidney function and are exposed to a high risk to evolve and reach end stage kidney disease with the need for renal replacement therapy (e.g dialysis or renal transplantation). In addition, patients with CKD are in most cases affected by other serious complications including cardiovascular disease, hyperlipidemia, anemia or metabolic bone disease where in many cases accurate and precise diagnosis and prognosis is not optimal.
Currently, we are far from optimal management of CKD patients in daily clinical practice which could be attributed to the lack of knowledge of early molecular mechanisms associated with the disease onset and the complex pathophysiological processes. At present, there is no effective treatment of CKD and there is a lack of early disease markers. Identification of novel and more reliable noninvasive biomarkers could be beneficial and straightforward for early detection and monitoring disease progression. The scope of this Research Topic is to improve the current state-of-the-art of its molecular mechanisms observed in CKD thorough investigation of the diagnostic/prognostic values of the protein profiles. The focus is on proteins as they reflect the functional output of an organism. Scientifically, this will take new directions in several aspects:
• Assessment of the proteomics data from animal models and humans to define and screen molecular changes associated with fibrosis process
• Comparability of large proteomic datasets for molecular changes of the key actors altered during fibrosis
• Computational analysis for evaluation of large datasets from the proteomics experiments and mapping molecular pathways underlying pathophysiology
• Identification of potential drug targets as a basis for further drug development. This will likely be translated into helpful tool to better handle and care patients with CKD which may be readily put into the hands of clinicians.
Here are interested specifically interested in receiving Original Research, Review Articles, and Case Studies
Proteome analysis has been applied in multiple studies in the context of chronic kidney disease, aiming to improving our knowledge on the molecular pathophysiology of the disease. The approach is generally based on the hypothesis that proteins are key in maintaining kidney function, and disease is a clinical consequence of a significant change of the protein level. Knowledge on critical proteins and their alteration in disease should in turn enable identification of ideal biomarkers that could guide patient management. In addition, all drugs currently employed target proteins. Hence, proteome analysis also promises to enable identifying the best suited therapeutic target, and, in combination with biomarkers, could be used as the rationale basis for personalized intervention.
Chronic kidney disease (CKD) is one of the most concerning diseases of our society both at the European scale and worldwide. CKD affects 10% of the adult population. 70 million Europeans have been diagnosed with some loss of their kidney function and are exposed to a high risk to evolve and reach end stage kidney disease with the need for renal replacement therapy (e.g dialysis or renal transplantation). In addition, patients with CKD are in most cases affected by other serious complications including cardiovascular disease, hyperlipidemia, anemia or metabolic bone disease where in many cases accurate and precise diagnosis and prognosis is not optimal.
Currently, we are far from optimal management of CKD patients in daily clinical practice which could be attributed to the lack of knowledge of early molecular mechanisms associated with the disease onset and the complex pathophysiological processes. At present, there is no effective treatment of CKD and there is a lack of early disease markers. Identification of novel and more reliable noninvasive biomarkers could be beneficial and straightforward for early detection and monitoring disease progression. The scope of this Research Topic is to improve the current state-of-the-art of its molecular mechanisms observed in CKD thorough investigation of the diagnostic/prognostic values of the protein profiles. The focus is on proteins as they reflect the functional output of an organism. Scientifically, this will take new directions in several aspects:
• Assessment of the proteomics data from animal models and humans to define and screen molecular changes associated with fibrosis process
• Comparability of large proteomic datasets for molecular changes of the key actors altered during fibrosis
• Computational analysis for evaluation of large datasets from the proteomics experiments and mapping molecular pathways underlying pathophysiology
• Identification of potential drug targets as a basis for further drug development. This will likely be translated into helpful tool to better handle and care patients with CKD which may be readily put into the hands of clinicians.
Here are interested specifically interested in receiving Original Research, Review Articles, and Case Studies
